Ying Liu

Ying Liu

Auto-generated profile, based on publicly available information

Ying Liu

Department of Endocrinology and Metabolism of Huashan Hospital, State Key Laboratory of Brain Function and Disorders, MOE Frontiers Center for Brain Science and the Institutes of Brain Science, Fudan University, Shanghai, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Journal of Diabetes Research
Verified
Journal Article
Open access
PDF file
YLYing Liu
Ying Liu
DWDi Wu
Di Wu
HZHangping Zheng
Hangping Zheng
YNYunzhi Ni
Yunzhi Ni
LZLu Zhu
Lu Zhu
RLRui Liu
Rui Liu
Background: Spexin is a novel peptide hormone and has shown antinociceptive effects in experimental mice. This study is aimed at evaluating the association of serum spexin level with diabetic peripheral neuropathy (DPN) and related pain in a Chinese population.Methods: We enrolled 167 type 2 diabetes mellitus (T2DM) including 56 patients without DPN (non‐DPN), 67 painless DPN, and 44 painful DPN. Serum spexin was measured using ELISA. Logistic regression models were performed to analyze the independent effects of spexin on prevalence of DPN and painful DPN. In streptozotocin (STZ)‐induced diabetic mice, mechanical pain threshold was measured using electronic von Frey aesthesiometer. Human peripheral blood mononuclear cells (PBMCs) were isolated and further stimulated with lipopolysaccharide without or with spexin. The gene expression was assayed by qPCR.Results: Compared with non‐DPN, serum spexin level decreased in painless DPN and further decreased in painful DPN. The odds of DPN was associated with low spexin level in T2DM, which was similar by age, sex, BMI, and diabetes duration, but attenuated in smokers. The odds of having pain was associated with decreased spexin level in DPN, which was similar by age, sex, smoking status, and diabetes duration, but attenuated in normal weight. Furthermore, we observed that mechanical pain threshold increased in spexin‐treated diabetic mice. We also found that lipopolysaccharide treatment increased the mRNA level of TNF‐α, IL‐6, and MCP‐1 in human PBMCs, while spexin treatment prevented this increase.Conclusions: These results suggested that spexin might serve as a protective factor for diabetes against neuropathology and pain‐related pathogenesis.

8 November 2025 in Diabetologia
Verified
Journal Article
Open access
PDF file
YJYaojing Jiang
Yaojing Jiang
DWDi Wu
Di Wu
YNYunzhi Ni
Yunzhi Ni
YLYing Liu
Ying Liu
HRHuixia Ren
Huixia Ren
RLRui Liu
Rui Liu
Aims/hypothesis Clinical studies revealed that serum spexin level is positively associated with beta cell function. However, the role of spexin in beta cells remains unclear. We hypothesise that spexin treatment could influence beta cell function and modulate glucose homeostasis in vivo. Methods We analysed glucose-stimulated insulin secretion (GSIS) and beta cell proliferation in mice and isolated mouse islets. Using mice fed a high-fat diet (HFD) and an HFD/streptozocin (STZ)-induced diabetes mouse model, we investigated the effects of spexin on glucose homeostasis and beta cell function. We performed a pull-down/MS assay and a cell-based binding assay to identify the binding partner of spexin on the beta cell surface. An ion pump activity assay and Atp1a1+/− mice were used to explore the underlying regulatory mechanisms. The effects of spexin on beta cell function were further measured on isolated human islets. Results We observed that spexin treatment increased GSIS in chow-diet-fed mice and isolated mouse islets. Spexin treatment also promoted beta cell proliferation in mouse islets and pancreatectomised mice. Furthermore, spexin treatment improved glucose tolerance in HFD-fed mice and attenuated hyperglycaemia in an HFD/STZ-induced diabetes mouse model, along with an elevated serum insulin level and increased beta cell proliferation. Spexin showed specific binding to the beta cell surface. The pull-down/MS assay demonstrated that spexin bound to the α1 subunit of sodium–potassium ATPase (ATP1A1), resulting in pump activity inhibition and subsequent membrane depolarisation. In Atp1a1+/− mice, which had 50% lower levels of ATP1A1, the effects of spexin on GSIS, beta cell proliferation and hyperglycaemia decreased. Importantly, spexin-treated human islets showed increased GSIS and proliferation. Conclusions/interpretation Our study highlights that spexin is a stimulatory factor for beta cell function and proliferation, and suggests that spexin is a diabetes therapeutic target for beta cell intervention. Graphical Abstract

23 June 2026 in Diabetologia
Verified
Journal Article
Open access
PDF file
YLYing Liu
Ying Liu
YNYunzhi Ni
Yunzhi Ni
CXChuantong Xie
Chuantong Xie
LFLinling Fan
Linling Fan
YJYaojing Jiang
Yaojing Jiang
RLRui Liu
Rui Liu
Aims/hypothesis: G-protein-coupled receptors (GPCRs) play an important role in maintaining systemic glucose homeostasis by regulating insulin secretion, with protein kinase A (PKA) signalling serving as a key downstream effector. Our previous work identified specific expression of type IIB PKA in pancreatic beta cells. Based on these findings, we propose that type IIB PKA is involved in mediating the GPCR signalling in pancreatic beta cells. Methods: The glucagon-like peptide-1 (GLP-1) analogue liraglutide was administered to mice 30 min before glucose injection during an IPGTT, whereas the glucose levels and insulin levels were measured in wild-type and RIIβ-knockout mice. The isolated islets were subjected to both perifusion assay and static batch incubations following stimulation with liraglutide, glucagon and follicle-stimulating hormone (FSH). RNA-seq analysis was performed to identify molecular changes in islets with RIIβ ablation. Both western blotting and quantitative PCR were employed to quantify the gene expression. Whole-cell patch-clamp recordings were conducted to measure K ATP and Ca 2+ currents. Insulin granule morphology and abundance were evaluated by electron microscopy and flow cytometry using EGFP-labelled Syncollin, respectively. Results: RIIβ-knockout mice exhibited impaired glucose tolerance and attenuated insulin secretion in response to liraglutide. Islets isolated from RIIβ-knockout mice showed reduced insulin secretion following liraglutide stimulation. Similarly, RIIβ-ablated islets displayed decreased insulin secretion in response to both glucagon and FSH. Further mechanistic studies revealed that RIIβ deficiency impaired liraglutide-mediated PKA signalling activation. Specifically, RIIβ-ablated beta cells exhibited reduced basal K ATP channel activity and lack of liraglutide-mediated channel inhibition. Multiple voltage-gated Ca 2+ channel genes were downregulated in RIIβ-ablated islets, leading to a mild reduction in basal Ca 2+ current and a significant decrease following liraglutide treatment. RIIβ-knockout beta cells also exhibited reduced insulin granule size, decreased total granule number and fewer granules docked at the plasma membrane. Conclusions/interpretation: Our results highlight type IIB PKA as a primary mediator of Gs-coupled receptor-potentiated insulin secretion, providing a new molecular framework for metabolic regulation research.